Navigation Links
Common diabetes drug may 'revolutionize' cancer therapies
Date:6/3/2009

This release is available in French.

Researchers at McGill University and the University of Pennsylvania have discovered that a widely used anti-diabetic drug can boost the immune system and increase the potency of vaccines and cancer treatments. Their findings will be published June 3 in the journal Nature.

The discovery was made by Dr. Russell Jones, an assistant professor at McGill's Goodman Cancer Centre and the Department of Physiology, Faculty of Medicine, Yongwon Choi, PhD, professor of pathology and laboratory medicine, and postdoctoral fellow Erika Pearce, PhD, of the University of Pennsylvania. They discovered that the widely prescribed diabetes treatment metformin increases the efficiency of the immune system's T-cells, which in turn makes cancer and virus-fighting vaccines more effective.

The specialized white blood cells of the human immune system known as "T-cells" remember pathogens they have encountered from previous infections or vaccinations, enabling them to fight subsequent infections much faster. This "immunological memory" has been the subject of intense study for many years, but until now the underlying cellular mechanisms behind it were not well understood. Now, the researchers say, they can use diabetic therapies to manipulate T-cell response and enhance the immune system's response to infections and cancer alike.

"Many genes involved in diabetes regulation also play a role in cancer progression," Jones explained. "There is also a significant body of data suggesting that diabetics are more prone to certain cancers. However, our study is the first to suggest that by targeting the same metabolic pathways that play a role in diabetes, you can alter how well your immune system functions."

"We serendipitously discovered that the metabolizing, or burning, of fatty acids by T-cells following the peak of infection is critical to establishing immunological memory," Pearce added. "We used metformin, which is known to operate on fatty-acid metabolism, to enhance this process, and have shown experimentally in mice that metformin increases T-cell memory as well as the ensuing protective immunity of an experimental anti-cancer vaccine."

Few talk about cancer and diabetes in the same breath. However, recent advances have uncovered common links between cancer and diabetes, in particular how metabolic pathways, the basic chemical reactions that happen in our cells, are controlled in these diseases. The recent findings suggest a new link between the metabolic pathways deregulated in cancer and diabetes and their role in immune cell function. The results suggest that common diabetic therapies which alter cellular metabolism may enhance T-cell memory, providing a boost to the immune system. This could lead to novel strategies for vaccine and anti-cancer therapies.

"Our findings were unanticipated, but are potentially extremely important and could revolutionize current strategies for both therapeutic and protective vaccines," Choi said.


'/>"/>

Contact: Cynthia Lee
cynthia.lee@mcgill.ca
514-398-6754
McGill University
Source:Eurekalert

Related medicine news :

1. HealthEdge(R) and Click4Care(R) Announce Common Leadership
2. Most common brain cancer may start in neural stem cells
3. Most common brain cancer may originate in neural stem cells
4. Bioniche Represented at House of Commons Sub-Committee on Food Safety
5. Common migraine pain condition also prevalent in cluster headache
6. WeissComm Group Acquires Common Sense Media Group, Appoints Founder Bob Pearson Chief Technology and Media Officer to Help Clients Evaluate and Optimize Social Media
7. Cogdell Spencer Announces Commencement of Common Stock Offering
8. Medivation Announces Offering of 2,750,000 Shares of Common Stock
9. Americans United for Life: Obama Nominates Avowed Judicial Activist Judge Who Undermines Common Ground
10. PET scan can non invasively measure early assessment of treatment for common type of breast cancer
11. Among Obese Diabetics, Sleep Apnea May Be Common
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... G-CON Manufacturing, ... Miniature, and Modular (PCMM) collaboration with Pfizer and GEA by designing and building ... The new PODs will provide tablet coating capability in the existing line at ...
(Date:9/25/2017)... ... September 25, 2017 , ... International Water Advocate Sharon ... Kleyne Hour Power of Water, Global Climate Change and Your Health on VoiceAmerica ... from a once-every-four-years series of events to a personal, daily Health Olympics. “Wouldn’t ...
(Date:9/25/2017)... ... September 25, 2017 , ... METTLER TOLEDO is pleased ... 25-26, 2017 in Los Angeles, CA. The symposium will feature speakers from North American ... today's mass calibration technologies and help with planning for the future of the modern ...
(Date:9/25/2017)... ... September 25, 2017 , ... Physician Partners of America ... at 5304 Main Street as an interventional pain management specialist. , Dr. Gorman ... He joins PPOA from private practice In Brooksville, Fla. His orthopedic background puts him ...
(Date:9/25/2017)... ... 25, 2017 , ... Earlypicker is expanding its offerings to include fashion, a ... Korean cosmetics and fashion trends sweeping the nation. The decision to expand beyond Korean ... great offerings that allow Koreans everywhere to look their best every single day. , ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... INDIANAPOLIS , Sept. 7, 2017  Eli ... today announced actions to streamline operations to more ... to improve its cost structure. Global workforce reductions, ... program, are expected to impact approximately 3,500 positions. ... the company expects annualized savings of approximately $500 ...
(Date:9/7/2017)... Sept. 7, 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade cell and tissue hypothermic storage ... Mike Rice , President and CEO, will be presenting ... Rodman & Renshaw 19 th Annual Global Investment ... (12:25 p.m. Pacific time). The conference is being held at ...
(Date:9/6/2017)... Eli Lilly and Company (NYSE: ... for galcanezumab and lasmiditan, two investigational treatments for migraine, ... (IHC) taking place Sept. 7-10 in Vancouver ... long-term data from an open-label study evaluating the safety ... and 240 mg) for the prevention of migraine. Galcanezumab ...
Breaking Medicine Technology: